Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Rohan Medhekar, PhD, Dionne Hines, MPH, PhD, Sumeet Panjabi, PhD, Tim Welliver, MD PhD, Xin Wang, PhD, Rolin L. Wade, RPh, MS

Blood (2018) 132 (Supplement 1): 836.

https://doi.org/10.1182/blood-2018-99-113414

Published: 2018

Journal Articles

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Bruno C Medeiros, MD, Bhavik J Pandya, PharmD, Chi-Chang Chen, PhD, Eric S. Groves, MD PhD, Cat N. Bui, PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS

Blood (2017) 130 (Supplement 1): 4694.

https://doi.org/10.1182/blood.V130.Suppl_1.4694.4694

Published: 2017

Journal Articles

Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US

Bhavik J Pandya, PharmD, Bruno C Medeiros, MD, Chi-Chang Chen, PhD, Samuel Wilson, PhD, Eric S. Groves, MD PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS

Blood (2017) 130 (Supplement 1): 2118.

https://doi.org/10.1182/blood.V130.Suppl_1.2118.2118

Published: 2017

Journal Articles

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

Victoria Divino, Mitch Dekoven, MHSA, Weiying Wang, MPH, Michael Kleinrock, MA, R. Donald Harvey, PharmD, Rolin L Wade, RPh, MS, Satyin Kaura, MSci, MBA

Blood (2014) 124 (21): 736.

https://doi.org/10.1182/blood.V124.21.736.736

Published: 2014

Journal Articles

The Burden Of Illness and Prevalence In Diffuse Large B-Cell (DLBCL) and Follicular (FL) Lymphomas

Edward J Dulac III, RPh, Karen A Joy, Roger Ndindjock, MPH, Katharine B Coyle, Rolin L Wade, RPh, MS

Blood (2013) 122 (21): 5619.

https://doi.org/10.1182/blood.V122.21.5619.5619

Published: 2013

NARROW

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

The Burden Of Illness and Prevalence In Diffuse Large B-Cell (DLBCL) and Follicular (FL) Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

The Burden Of Illness and Prevalence In Diffuse Large B-Cell (DLBCL) and Follicular (FL) Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only